Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Rabies Monomab CBB 1 in Healthy People
NCT05832073Phase 1Unknown
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBB1 in rabies (3 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Safety evaluation index at 12 months. Status: unknown.
02
Drugs
CBB1
03
Conditions
rabies
Beyond the preview
Go deeper on NCT05832073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832073.